The Endothelium-Derived Hyperpolarizing Factor Puzzle
2005; Lippincott Williams & Wilkins; Volume: 111; Issue: 6 Linguagem: Inglês
10.1161/01.cir.0000156405.75257.62
ISSN1524-4539
Autores Tópico(s)Renin-Angiotensin System Studies
ResumoHomeCirculationVol. 111, No. 6The Endothelium-Derived Hyperpolarizing Factor Puzzle Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBThe Endothelium-Derived Hyperpolarizing Factor PuzzleA Mechanism Without a Mediator? Richard A. Cohen, MD Richard A. CohenRichard A. Cohen From the Vascular Biology Unit, Department of Medicine, Boston University School of Medicine, Boston, Mass. Originally published15 Feb 2005https://doi.org/10.1161/01.CIR.0000156405.75257.62Circulation. 2005;111:724–727The article by Scotland et al1 published in this issue of Circulation reports on a unique mouse model that might help to identify a longstanding, intensely investigated, and controversial substance called endothelium-derived hyperpolarizing factor (EDHF). EDHF is a "holy grail," a "third factor" that provides local control of vascular homeostasis in addition to nitric oxide (NO) and prostacyclin. The discovery of the latter substances, which are known to cause both hyperpolarization and relaxation, led to Nobel prizes. But beware acronyms! The term EDHF is >15 years old, and as yet no one substance and no one mechanism has been proposed that explains all of its features. The story of the investigation has been a meandering one, with many stops along the way. Each stop has taught us how blood vessels function, but there is more to be learned if we are to have a complete understanding.See p 796Twenty-five years ago, Robert Furchgott identified that acetylcholine and bradykinin generated a diffusible, short-lived mediator from endothelial cells that relaxed underlying smooth muscle cells by a mechanism similar to that of nitrovasodilators.2 This seminal observation led to the identification of the substance as NO, contributed in a major way to the growth of vascular biology,3 and increased our understanding of why cardiovascular risk factors and disease diminish vasodilatation. Notwithstanding the importance of NO and cyclic guanosine monophosphate (cGMP), the major intracellular mediator of NO-induced smooth muscle relaxation, many of us in the field have had the nagging feeling that something was missing.4 That this feeling is warranted is no better exemplified than by the findings of Scotland et al.1 These authors show that transgenic mice devoid of endothelial NO synthase (eNOS) and cyclooxygenase (COX)-1 maintain a mechanism by which acetylcholine can hyperpolarize, relax, and vasodilate resistance blood vessels. Because their experimental strategy seemingly excludes the enzymatic sources of NO and prostacyclin, the authors conclude that a non-NO, nonprostacyclin substance must be involved. Furthermore, they make the fascinating observation that the mechanism shows a marked gender preference for female mice. To help the reader put the authors' observations in perspective, I would like to briefly discuss their findings in relationship to our prior knowledge and current understanding of EDHF and to suggest potential fruitful areas of investigation. Scotland et al1 review the pertinent literature, and the subject of EDHF has been reviewed in depth in Circulation by this author and a colleague,4 and more recently by leaders in the field.5What Is EDHF and What Is Its Endothelial Source?Since the original description that the endothelium-dependent vasodilator acetylcholine causes smooth muscle hyperpolarization6 (and, hence, coining of the term EDHF7), considerable research has been done to identify a factor that, like NO, diffuses from the endothelium and hyperpolarizes the smooth muscle cell. Hyperpolarization is thought to promote relaxation by inhibiting voltage-dependent calcium channels, although there are other possibilities.4 Despite the research, no consensus has been reached as to the mediator of endothelium-dependent hyperpolarization or its mechanism of action. It has always been assumed that the mediator and mechanism of EDHF supplements the actions of NO and prostacyclin, both of which are confirmed endothelium-derived hyperpolarizing and relaxing factors.4,8 Indeed, vascular hyperpolarization and relaxation in the presence of inhibitors of NOS and COX-1 have been taken to be synonymous with EDHF. Scotland et al1 show that these inhibitors leave a substantial portion of the mesenteric artery relaxation to acetylcholine or bradykinin intact. By showing that the aortic relaxation to acetylcholine is blocked by the same inhibitors, they also demonstrate another characteristic of EDHF. Although some large arteries, in particular, pig, bovine, and human coronary arteries, have potent EDHF mechanisms, this mechanism appears to be most important in small arteries that account for vascular resistance and therefore blood pressure regulation.NO was in part identified as a short-lived endothlium derived relaxing factor (EDRF) by its ability to diffuse from an artery with intact endothelium and to relax a neighboring artery denuded of endothelium. Unfortunately, except under special circumstances, inhibitors of NOS and COX-1 block the substantial relaxing factor present in the perfusate of arteries with intact endothelium.4,5,9 This leaves open the possibility that EDHF is even more short-lived than NO or that it is present in too low a concentration to function in such an experiment. Nevertheless, the hyperpolarization and relaxation of arteries, which persist in the presence of NOS and COX-1 inhibitors, bear some resemblance to EDRF. The response requires an intact endothelium and an increase in endothelial intracellular Ca2+ levels, which activates a calmodulin-dependent mechanism similar to that required for eNOS.10 Derivatives of endothelial cell arachidonic acid have been suspected to be EDRF even since the first report,2 and this possibility is compatible with increased activity of Ca2+-dependent phospholipase A2, which releases large amounts of arachidonic acid from endothelial cells stimulated by acetylcholine or bradykinin. Inhibitors of cytochrome P450, a major pathway of nonprostanoid arachidonic acid metabolism, were recognized early on to inhibit endothelium-dependent relaxation, and products of this enzyme, eicosatetraenoic acids (EETs), were shown to directly activate potassium channels and to cause smooth muscle cell hyperpolarization and relaxation. The difficulty of bioassaying a diffusable hyperpolarizing or relaxing factor in the presence of NOS and COX-1 inhibitors has led to the conclusion that although EETs may be involved, they may instead act primarily on endothelial cell potassium channels to hyperpolarize that cell. Unlike smooth muscle cells, endothelial cells are devoid of typical voltage-sensitive Ca2+ channels, and hyperpolarization promotes Ca2+ entry into the cell through nonselective ion channels. This in turn may further stimulate as-yet unidentified Ca2+-dependent processes in the endothelium that promote vascular relaxation. One interesting proposal is that opening of endothelial K+ channels, perhaps mediated by EETs, allows for the efflux of potassium from endothelial cells in sufficient amounts that it hyperpolarizes the smooth muscle cells.5 This suggestion depends on endothelium-dependent smooth muscle cell hyperpolarization occurring via inward rectifier potassium channels and Na+/K+ ATPase, both of which are stimulated by low concentrations of K+. K+ as an EDHF remains a possibility, and its dilution in solution may explain why it is difficult to bioassay. Nevertheless, identification of a non-NO, nonprostanoid factor that is released from endothelial cells in sufficient amounts to cause smooth muscle hyperpolarization is lacking. What explains the fact that after 20 years of investigation, no factor has been found?One issue is that many of the experimental observations have necessarily required the use of pharmacological inhibitors that may not block 100% of the intended target or that lack specificity. For instance, cytochrome P450 inhibitors used in early experiments were later shown to block potassium channels. Also, NOS inhibitors, which have been widely used to exclude the role of NO, may not completely inhibit NO release, and their efficacy has rarely been verified. As an example, 8 years ago my colleagues and I were in the midst of investigating the mechanisms of endothelium-dependent relaxation of the rabbit carotid artery. This blood vessel has all of the typical characteristics of EDHF, including endothelium-dependent hyperpolarization and relaxation that persist in the presence of NOS and COX-1 inhibitors,11 which are blocked by K+ channel and cytochrome P450 inhibitors. Using 2 separate methods of measurement, we made the striking finding that despite using high concentrations of NOS inhibitors, almost 30% of the release of nitric oxide persisted, and the hyperpolarization and relaxation of the artery in the presence and absence of the NOS inhibitors correlated with NO release.8 This may simply be because the NOS inhibitors that are generally used are competitive antagonists that by their nature do not provide insurmountable blockade of arginine use by NOS. Also, smaller arteries with EDHF-like properties such as the rabbit carotid artery release higher amounts of NO that are more difficult to block with inhibitors.12Scotland et al1 appear to have circumvented any possibility that they did not prevent the release of NO or prostacyclin because they used genetic deletion of both the enzymes that normally produce them. They demonstrated that prostacyclin release was diminished in the blood of the mice they studied. They did not, however, evaluate whether NO was eliminated. This possibility would seem to be unlikely were it not for a series of elegant studies by Meng et al,13 who showed that in small cerebral pial blood vessels of the eNOS-deficient mouse, endothelium-dependent vasodilation persists. These authors showed that through a striking demonstration of genetic flexibility, the persistent responses are mediated by the other calcium-dependent NOS isoform, neuronal NOS (nNOS), that replaces the deleted eNOS in the endothelium.13 Although neither the authors nor the reviewers of the article by Scotland et al1 appear to have been aware of this work, Scotland et al did show that addition of NOS inhibitor to the arteries deficient in eNOS had no further effect. Although this should obviate any possibility that release of NO persists, nNOS is particularly difficult to completely inhibit, and it is possible that nNOS is producing something other than NO that is unimpeded by NOS inhibitors.14 Finally, the female gender preference for the EDHF response is compatible with an increased expression of nNOS caused by estrogen.15Until recently, the possibility that NOS could produce a mediator other than NO that could function as an EDHF would have seemed unlikely. Like Scotland and associates, however, Matoba et al16 showed that hyperpolarizing responses to acetylcholine of mouse mesenteric arteries resisted NOS and COX-1 inhibitors and persisted in eNOS-deficient mice. They showed that catalase inhibited acetylcholine-induced hyperpolarization and relaxations that persisted in the presence of the NOS and COX-1 inhibitors in wild-type mice, and proposed that hydrogen peroxide produced by eNOS is EDHF. Morikawa et al17 provided evidence that strengthened the prospects that hydrogen peroxide may be a NOS-derived vasodilator by showing that mice deficient in Cu/Zn superoxide dismutase, which catalyzes the formation of hydrogen peroxide from superoxide anion, display diminished EDHF vascular responses. They concluded that superoxide dismutase may be an "EDHF synthase." In our own studies, we found that the rabbit carotid artery still relaxed to acetylcholine, despite blocking superoxide dismutase activity.12 As expected, however, this relaxation greatly increased superoxide levels and decreased the ability of NO to stimulate cGMP. This suggests the possibility that NO released from NOS reacts with superoxide anion to form the product peroxynitrite, which might constitute another mediator of relaxation.12 Further research is required to determine the precise role of hydrogen peroxide, peroxynitrite, and perhaps other reactive oxygen and nitrogen species as EDHF.How Does EDHF Relax Vascular Smooth Muscle?For NO, the simple view is that relaxation of smooth muscle occurs through the stimulation of guanylyl cyclase to produce its product, cGMP, which causes multiple protein kinase G substrates to decrease intracellular Ca2+ and inhibit contractile proteins to relax smooth muscle. For EDHF, without knowing precisely what the mediator is, it is difficult to define precisely how hyperpolarization of the smooth muscle occurs. Nevertheless, inward rectifier K+ channels and Na+/K+ ATPase were identified and shown by the use of barium and ouabain, respectively, to play a role in endothelium-dependent hyperpolarization. Scotland et al1 show that these inhibitors, and, in addition, removal of the endothelium, prevent the residual relaxations in the mesenteric arteries of mice deficient in NOS and COX-1.Another important mechanism by which endothelial cells cause smooth muscle hyperpolarization arose when it was realized that electrical conductance can occur directly from endothelium to smooth muscle. An anatomic feature called "gap junctions," formed between the cells by connexin proteins, underlie this property. They are present particularly in small arteries where the apposition of the 2 cells is closest, potentially explaining the larger role for EDHF in small arteries. Inhibitors of gap junctions block the hyperpolarization caused by acetylcholine in smooth muscle cells of guinea pig mesenteric arteries without blocking the hyperpolarization of the endothelium, suggesting the importance of this mechanism.18 Thus, EDHF may not be an enzymatically derived "factor" that, like NO and prostacyclin, diffuses from endothelial cells to smooth muscle; rather it may be a phenomenon that begins as a calcium-activated event that hyperpolarizes the endothelium and a signal that is transferred to the smooth muscle by K+ or via gap junctions. The endothelial hyperpolarization could be initiated by EETs or NOS-derived NO, hydrogen peroxide, peroxynitrite, or other reactive species.As mentioned above, the hyperpolarization and relaxation of the rabbit carotid artery persist in the presence of NOS and COX-1 inhibitors but can be explained by the NO release that persists. More striking is that despite the residual NO, the NOS inhibitors largely prevent the rise in smooth muscle cGMP, suggesting that NO may mediate hyperpolarization and relaxation of the smooth muscle by other means. One possibility is that NO can activate K+ channels by a thiol redox-dependent mechanism.19 Another is that NO may regulate other mechanisms of membrane potential regulation such as Na+/K+ ATPase. Still another is that NO, without the aid of cGMP, increases the activity of the sarco(endo)plasmic reticulum Ca2+ ATPase (SERCA). This in turn increases intracellular stores of Ca2+, resulting in the closing of store-operated, nonselective ion channels.20 Because these channels conduct Na2+ in addition to Ca2+, their closing hyperpolarizes the smooth muscle cell membrane. We recently demonstrated the molecular mechanism by which NO activates SERCA via formation of peroxynitrite within smooth muscle cells, which in turn S-glutathiolates reactive cysteine thiols on SERCA.21 Indeed, SERCA was S-glutathiolated during endothelium-dependent relaxation of the rabbit carotid artery, consistent with this mechanism.Where Do We Go From Here?This story, like any search for a holy grail, is long and complex, but I think it is fair to conclude that much productive research has been performed in pursuit of the goal of more fully understanding the mechanisms of vasodilatation. Clearly, the story goes well beyond NO and cGMP.4 Other mediators, including NOS-derived reactive oxygen and nitrogen species, as well as arachidonic acid derivatives, are likely to be involved. We have moved well beyond the simple concept of diffusable endothelial factors to a need for deeper understanding of the mechanisms by which endothelial cell Ca2+ is regulated and by which endothelial membrane potential is regulated and transmitted to the smooth muscle. The mechanisms by which smooth muscle relaxes involve multiple pathways, and an integrated approach is required to fully understand vasodilation. Such an experimental approach requires new methodologies to monitor not only Ca2+ but also K+, Na+, and Cl− ions, along with membrane potential and vessel diameter. New concepts of redox regulation by reactive oxygen and nitrogen species need to be integrated with our knowledge of the function of ion channels and transporters, as well as contractile proteins. The physiological responses must be correlated with measurements of the suspected mediators, whether they be intra- or extracellular, so that their role is validated.With good reason, Scotland et al1 suggest that the mouse model that they have created provides an excellent model with which to identify and further understand EDHF. They provide evidence that without eNOS or COX-1 a major mechanism of blood pressure control remains that counters the hypertension that is expected from the lack of eNOS. Understanding the mechanism is a worthy goal with great potential for the development of therapeutics, particularly for systemic and pulmonary hypertension. Scotland et al provide the "teaser" that the vasodilator mechanism observed in their female double-knockout mice might help to explain the relative cardioprotection enjoyed by women. If this is true, then their findings will have epidemiological importance as well.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.FootnotesCorrespondence to Richard A. Cohen, MD, Director, Vascular Biology Unit, X708, Dept of Medicine, Boston University School of Medicine, 650 Albany St, Boston, MA 02118. E-mail [email protected] References 1 Scotland RS, Madhani M, Cauhan S, Moncada S, Andresen J, Nilsson H, Hobbs AJ, Ahluwalia A. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation. 2005; 111: 796–803.LinkGoogle Scholar2 Furchgott RF, Zawadzki JV. The obligatory role of the endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980; 288: 373–376.CrossrefMedlineGoogle Scholar3 Cohen RA. The potential clinical impact of 20 years of nitric oxide research. Am J Physiol. 1999; 276: H1404–H1407.MedlineGoogle Scholar4 Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization: beyond nitric oxide and cyclic GMP. Circulation. 1995; 92: 3337–3349.CrossrefMedlineGoogle Scholar5 Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci. 2002; 23: 374–380.CrossrefMedlineGoogle Scholar6 Bolton TB, Lang RJ, Takewaki T. Mechanism of action of noradrenaline and carbachol on smooth muscle guinea-pig anterior mesenteric artery. J Physiol. 1984; 351: 549–572.CrossrefMedlineGoogle Scholar7 Chen G, Suzuki H, Weston AH. Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol. 1988; 95: 1165–1174.CrossrefMedlineGoogle Scholar8 Cohen RA, Plane F, Najibi S, Huk I, Malinski T, Garland CJ. Nitric oxide is the mediator of both endothelium-dependent relaxation and hyperpolarization of the rabbit carotid artery. Proc Natl Acad Sci U S A. 1997; 94: 4193–4198.CrossrefMedlineGoogle Scholar9 Kauser K, Rubanyi GM. Bradykinin-induced, N-nitro-l-arginine-insensitive endothelium-dependent relaxation of porcine coronary arteries is not mediated by bioassayable relaxing substances. J Cardiovasc Pharmacol. 1992; 20: S101–S104.CrossrefMedlineGoogle Scholar10 Nagao T, Illiano S, Vanhoutte PM. Calmodulin antagonists inhibit endothelium-dependent hyperpolarization in the canine coronary artery. Br J Pharmacol. 1992; 107: 382–386.CrossrefMedlineGoogle Scholar11 Cowan CL, Palacino JJ, Najibi S, Cohen RA. Potassium channel mediated relaxation to acetylcholine in rabbit arteries. J Pharmacol Exp Ther. 1993; 266: 1482–1489.MedlineGoogle Scholar12 Pagano PJ, Griswold MC, Najibi S, Marklund SL, Cohen RA. Resistance of endothelium-dependent relaxation elevation of O2− levels in rabbit carotid artery. Am J Physiol Heart Circ Physiol. 1999; 46: H2109–H2114.Google Scholar13 Meng W, Ayata C, Waeber C, Huang PL, Moskowitz MA. Neuronal NOS-cGMP-dependent ACh-induced relaxation in pial arterioles of endothelial NOS knockout mice. Am J Physiol. 1998; 274: H411–H415.CrossrefMedlineGoogle Scholar14 Heinzel B, John M, Klatt P, Bohme E, Mayer B. Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J. 1992; 281: 627–630.CrossrefMedlineGoogle Scholar15 Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A. 1994; 91: 5212–5216.CrossrefMedlineGoogle Scholar16 Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K, Kanaide H, Takeshita A. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest. 2000; 106: 1521–1530.CrossrefMedlineGoogle Scholar17 Morikawa K, Shimokawa H, Matoba T, Kubota H, Akaike T, Talukder MA, Hatanaka M, Fujiki T, Maeda H, Takahashi S, Takeshita A. Pivital role of Cu,Zn-superoxide dismutase in endothelium-dependent hyperpolarization. J Clin Invest. 2003; 112: 1871–1879.CrossrefMedlineGoogle Scholar18 Yamamoto Y, Imaeda K, Suzuki H. Endothelium-dependent hyperpolarization and intercellular electrical coupling in guinea-pig mesenteric arterioles. J Physiol. 1999; 514: 505–513.CrossrefMedlineGoogle Scholar19 Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle cells. Nature. 1994; 368: 850–853.CrossrefMedlineGoogle Scholar20 Cohen RA, Weisbrod RM, Gericke M, Yaghoubi M, Bierl C, Bolotina VM. Mechanism of nitric oxide-induced vasodilatation. Refilling of intracellular stores by sarcoplasmic reticulum Ca2+ ATPase and inhibition of store-operated Ca2+ influx. Circ Res. 1999; 84: 210–219.CrossrefMedlineGoogle Scholar21 Adachi T, Weisbrod RM, Pimentel D, Ying J, Sharov VS, Schoneich C, Cohen RA. S-Glutathiolation by peroxynitrite activates SERCA during arterial relaxation by nitric oxide. Nat Med. 2004; 10: 1200–1207.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Wang H, Li S, Wang X, He C, Wang T, Wang Y and Guo W (2020) Vasodilation activity of dipfluzine metabolites in isolated rat basilar arteries and their underlying mechanisms, Environmental Toxicology and Pharmacology, 10.1016/j.etap.2020.103430, 79, (103430), Online publication date: 1-Oct-2020. Chen S, Zhang J, Hu Y, Hu D, Gao S, Fan Y, Wang Y, Jiao Y and Chen Z (2018) Total Flavones of Rhododendron simsii Planch Flower Protect against Cerebral Ischemia-Reperfusion Injury via the Mechanism of Cystathionine- γ -Lyase-Produced H 2 S , Evidence-Based Complementary and Alternative Medicine, 10.1155/2018/8903849, 2018, (1-11), Online publication date: 31-May-2018. Han J, Xu H, Chen X, Hu H, Hu K, Chen Z and He G (2018) Total Flavone of Rhododendron Improves Cerebral Ischemia Injury by Activating Vascular TRPV4 to Induce Endothelium-Derived Hyperpolarizing Factor-Mediated Responses, Evidence-Based Complementary and Alternative Medicine, 10.1155/2018/8919867, 2018, (1-12), Online publication date: 11-Oct-2018. Orlov S, Gusakova S, Smaglii L, Koltsova S and Sidorenko S (2017) Vasoconstriction triggered by hydrogen sulfide: Evidence for Na + ,K + ,2Cl - cotransport and L-type Ca 2+ channel-mediated pathway, Biochemistry and Biophysics Reports, 10.1016/j.bbrep.2017.09.010, 12, (220-227), Online publication date: 1-Dec-2017. Peter E, Varma J and Kevil C (2015) Hydrogen Sulfide Atherosclerosis, 10.1002/9781118828533.ch31, (393-403) Mustafa A, Sikka G, Gazi S, Steppan J, Jung S, Bhunia A, Barodka V, Gazi F, Barrow R, Wang R, Amzel L, Berkowitz D and Snyder S (2011) Hydrogen Sulfide as Endothelium-Derived Hyperpolarizing Factor Sulfhydrates Potassium Channels, Circulation Research, 109:11, (1259-1268), Online publication date: 11-Nov-2011. Bolognesi M, Zampieri F, Di Pascoli M, Verardo A, Turato C, Calabrese F, Lunardi F, Pontisso P, Angeli P, Merkel C, Gatta A and Sacerdoti D (2011) Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats, Liver International, 10.1111/j.1478-3231.2011.02509.x, 31:6, (881-890), Online publication date: 1-Jul-2011. Zhang D and Gutterman D (2011) Transient Receptor Potential Channel Activation and Endothelium-dependent Dilation in the Systemic Circulation, Journal of Cardiovascular Pharmacology, 10.1097/FJC.0b013e3181fd35d1, 57:2, (133-139), Online publication date: 1-Feb-2011. Gao F and Wang D (2010) Hypotension induced by activation of the transient receptor potential vanilloid 4 channels: role of Ca2+-activated K+ channels and sensory nerves, Journal of Hypertension, 10.1097/HJH.0b013e328332b865, 28:1, (102-110), Online publication date: 1-Jan-2010. Burger N, Kuzina O, Osol G and Gokina N (2009) Estrogen replacement enhances EDHF-mediated vasodilation of mesenteric and uterine resistance arteries: role of endothelial cell Ca 2+ , American Journal of Physiology-Endocrinology and Metabolism, 10.1152/ajpendo.90517.2008, 296:3, (E503-E512), Online publication date: 1-Mar-2009. Rose R and Giles W (2008) Natriuretic peptide C receptor signalling in the heart and vasculature, The Journal of Physiology, 10.1113/jphysiol.2007.144253, 586:2, (353-366), Online publication date: 15-Jan-2008. COLWELL J, LYONS T, KLEIN R, LOPES-VIRELLA M and JOKL R (2008) ATHEROSCLEROSIS AND THROMBOSIS IN DIABETES MELLITUS: NEW ASPECTS OF PATHOGENESIS Levin and O'Neal's The Diabetic Foot, 10.1016/B978-0-323-04145-4.50012-0, (89-113), . Brocq M, Leslie S, Milliken P and Megson I (2008) Endothelial Dysfunction: From Molecular Mechanisms to Measurement, Clinical Implications, and Therapeutic Opportunities, Antioxidants & Redox Signaling, 10.1089/ars.2007.2013, 10:9, (1631-1674), Online publication date: 1-Sep-2008. Raffetto J and Khalil R (2008) Mechanisms of varicose vein formation: valve dysfunction and wall dilation, Phlebology: The Journal of Venous Disease, 10.1258/phleb.2007.007027, 23:2, (85-98), Online publication date: 1-Apr-2008. Capdevila J (2007) Regulation of ion transport and blood pressure by cytochrome p450 monooxygenases, Current Opinion in Nephrology & Hypertension, 10.1097/MNH.0b013e32827ab48c, 16:5, (465-470), Online publication date: 1-Sep-2007. Selemidis S and Cocks T (2007) Smooth muscle mediates circumferential conduction of hyperpolarization and relaxation to focal endothelial cell activation in large coronary arteries, Naunyn-Schmiedeberg's Archives of Pharmacology, 10.1007/s00210-007-0149-7, 375:2, (85-94), Online publication date: 13-Mar-2007. Si H, Heyken W, Wölfle S, Tysiac M, Schubert R, Grgic I, Vilianovich L, Giebing G, Maier T, Gross V, Bader M, de Wit C, Hoyer J and Köhler R (2006) Impaired Endothelium-Derived Hyperpolarizing Factor-Mediated Dilations and Increased Blood Pressure in Mice Deficient of the Intermediate-Conductance Ca2+-Activated K+ Channel, Circulation Research, 99:5, (537-544), Online publication date: 1-Sep-2006. Matsumoto T, Miyamori K, Kobayashi T and Kamata K (2006) Specific impairment of endothelium-derived hyperpolarizing factor-type relaxation in mesenteric arteries from streptozotocin-induced diabetic mice, Vascular Pharmacology, 10.1016/j.vph.2006.02.007, 44:6, (450-460), Online publication date: 1-Jun-2006. Moncada S and Higgs E Nitric Oxide and the Vascular Endothelium The Vascular Endothelium I, 10.1007/3-540-32967-6_7, (213-254) February 15, 2005Vol 111, Issue 6 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000156405.75257.62PMID: 15710775 Originally publishedFebruary 15, 2005 KeywordsEditorialsvasodilationendotheliumPDF download Advertisement SubjectsAnimal Models of Human DiseaseEndothelium/Vascular Type/Nitric OxidePharmacologyVascular Biology
Referência(s)